Browsing by Author "Simsek, T"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    The Effects of Fibroblast Growth Factor-2 Blocking on Development of Chick Cervical Vertebra and Relationship with Oxidative Stress and Apoptosis
    Duransoy, YK; Simsek, T; Öztürk, F; Mete, M; Tuglu, MI; Selçuki, M
    Fibroblast growth factor (FGF) plays a role in the development of bone and cartilage. FGF-2 is a member of this family and blocking of FGF-2 affects the bone development. In this study, effects of FGF-2 blocking on the formation of vertebrae in chick embryos before ossifications and orientation of cervical vertebrae were investigated with histological examinations. In this study, anti-FGF-2 was performed to chick embryos at E4th and E10th days. Samples were taken in E15th days and changes in the cervical spine were evaluated as histochemically (with hematoxylin-eosin, Alizarin red, Masson's trichrome staining) and immunohistochemically (with iNOS, eNOS and TUNEL). Also changings were evaluated by morphometric analysis. In macroscopic examination of the cervical vertebrae significant difference was not detected. But in histochemical staining, defects were observed in cartilage and ossification process. Increasing in oxidative stress was demonstrated by iNOS and eNOS. Also apoptosis which was represented by tunnel was found to be increased. FGF-2 blocking affects the ossification process in the cervical spine by inducing oxidative stress and apoptosis which results with cell death.
  • No Thumbnail Available
    Item
    A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer
    Dursun, P; Erkanli, S; Güzel, AB; Gultekin, M; Tarhan, NC; Altundag, O; Demirkiran, F; Bese, T; Yildirim, Y; Bozdag, G; Yarali, H; Simsek, T; Ozcelik, B; Ortaç, F; Taskin, S; Guvenal, T; Ozgul, N; Haberal, A; Vardar, MA; Dede, M; Yenen, M; Altintas, A; Arvas, M; Ayhan, A
    Objective: To analyze the results of fertility-sparing treatment of early-stage endometrial cancer (EC) in patients treated at Turkish gynecologic oncology centers, and to present a review of the literature. Methods: Thirteen healthcare centers in Turkey were contacted to determine if they were eligible to participate in the study. Centers that were eligible and agreed to participate were sent a database form to record the demographic characteristics, clinicopathologic findings, and follow-up results for their EC patients. Results: Eleven Turkish healthcare centers provided data on 43 EC patients. Mean duration of treatment was 5 months and mean follow-up was 49 months. In total, 35 (81.4%) patients were tumor free following primary progesterone therapy. Mean time from the end of progesterone therapy to pregnancy was 10.6 +/- 4.3 months (range, 3-18 months). Two patients had tumor recurrence during follow-up. The pregnancy rate among the 31 women who actively sought pregnancy was 41.9% (n = 13). Conclusion: Conservative management of early-stage EC in women of reproductive age using oral progestins was effective and did not compromise oncological outcome. Pregnancy in the study patients was achieved spontaneously and artificially. (C) 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    CLINICOPATHOLOGIC AND SURGICAL ANALYSIS OF 1090 PATIENTS WITH BORDERLINE OVARIAN TUMORS: A TURKISH SOCIETY GYNECOLOGIC ONCOLOGY (TRSGO) MULTI-INSTITUTIONAL RETROSPECTIVE TRIAL
    Guvenal, T; Demirkiran, F; Simsek, E; Yalcin, Y; Khatib, G; Gokulu, SG; Simsek, T; Dolapcioglu, K; Onan, A; Ozgul, N; Ortac, F; Yuksel, H; Altintas, A; Boso, B; Seyfettinoglu, S; Celik, C; Ureyen, I; Yalcin, I; Gungorduk, K; Senturk, B; Ayhan, A
  • No Thumbnail Available
    Item
    Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART)
    Ecevit, MC; Özcan, M; Can, IH; Tatar, EC; Özer, S; Esen, E; Atan, D; Göde, S; Elsurer, C; Eryilmaz, A; Coskun, BU; Yazici, ZM; Dinç, ME; Ozdogan, F; Gunhan, K; Bilal, N; Korkut, AY; Kasapoglu, F; Türk, B; Server, EA; Çelebi, ÖÖ; Simsek, T; Kum, RO; Adali, MK; Eren, E; Aslier, NGY; Bayindir, T; Çetin, AC; Göker, AE; Güvenç, IA; Köseoglu, S; Özler, GS; Sahin, E; Yilmaz, AS; Güne, C; Yildirim, GA; Öca, B; Durmusoglu, M; Kantekin, Y; Özmen, S; Kubat, GO; Sanal, SK; Altuntas, EE; Selçuk, A; Yazici, H; Baklaci, D; Yaylaci, A; Hanci, D; Dogan, S; Fidan, V; Uygur, K; Keles, N; Cingi, C; Topuz, B; Çanakçioglu, S; Önerci, M
    Object: To prepare a national guideline for Oto-rhinolaryngologist who treat allergic rhinitis patients Methods: The study was conducted by three authors, namely the writing support team. The support team made the study plan, determined the writing instructions, chose the subgroups including the advisory committee, the advisors for authors and the authors. A workshop was organized at the very beginning to explain the details of the study to the team. Advisors took the chance to meet their coworkers in their subgroups and determined the main headings and subheadings of the guideline, together with the authors. After key words were determined by the authors, literature search was done in various databases. The authors keep in touch with the advisors and the advisors with the advisory committee and the support group at every stage of the study. National and International published articles as well as the abstracts of unpublished studies, imperatively presented in National Congresses, were included in this guideline. Only Guideline and meta-analyses published in last seven years (2013- 2017) and randomized controlled studies published in last two years (2015- 2017) were included. After all work was completed by the subgroups, support team brought all work together and edited the article. Results: A detailed guideline about all aspects of allergic rhinitis was created. Conclusion: The authors believe that this guideline will enable a compact and up-to-date information on allergic rhinitis to healthcare professionals. This guideline is the first in the field of Otolaryngology in Turkey. It should be updated at regular intervals.
  • No Thumbnail Available
    Item
    Multicenter Analysis of Gestational Trophoblastic Neoplasia in Turkey
    Ozalp, SS; Telli, E; Oge, T; Tulunay, G; Boran, N; Turan, T; Yenen, M; Kurdoglu, Z; Ozler, A; Yuce, K; Ulker, V; Arvas, M; Demirkiran, F; Bese, T; Tokgozoglu, N; Onan, A; Sanci, M; Gokcu, M; Tosun, G; Dikmen, Y; Ozsaran, A; Terek, MC; Akman, L; Yetimalar, H; Kilic, DS; Gungor, T; Ozgu, E; Yildiz, Y; Kokcu, A; Kefeli, M; Kuruoglu, S; Yuksel, H; Guvenal, T; Hasdemir, PS; Ozcelik, B; Serin, S; Dolanbay, M; Arioz, DT; Tuncer, N; Bozkaya, H; Guven, S; Kulaksiz, D; Varol, F; Yanik, A; Ogurlu, G; Simsek, T; Toptas, T; Dogan, S; Camuzoglu, H; Api, M; Guzin, K; Caliskan, E; Doger, E; Cakmak, B; Ilhan, TT
    Background: To evaluate the incidence, diagnosis and management of GTN among 28 centers in Turkey. Materials and Methods: A retrospective study was designed to include GTN patients attending 28 centers in the 10-year period between January 2003 and May 2013. Demographical characteristics of the patients, histopathological diagnosis, the International Federation of Gynecology and Obstetrics (FIGO) anatomical and prognostic scores, use of single-agent and multi-agent chemotherapy, surgical interventions and prognosis were evaluated. Results: From 2003-2013, there were 1,173,235 deliveries and 456 GTN cases at the 28 centers. The incidence was calculated to be 0.38 per 1,000 deliveries. According to the evaluated data of 364 patients, the median age at diagnosis was 31 years (range, 15-59 years). A histopathological diagnosis was present for 45.1% of the patients, and invasive mole, choriocarcinoma and PSTTs were diagnosed in 22.3% (n=81), 18.1% (n=66) and 4.7% (n=17) of the patients, respectively. Regarding final prognosis, 352 (96.7%) of the patients had remission, and 7 (1.9%) had persistence, whereas the disease was mortal for 5 (1.4%) of the patients. Conclusions: Because of the differences between countries, it is important to provide national registration systems and special clinics for the accurate diagnosis and treatment of GTN.